Rob Abbott – CEO, ISPOR
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
ABBOTT LABORATORIES is an American-based, global, diversified healthcare firm. Among the world’s largest and most successful corporations, ABBOTT has a presence in more than 160 countries.
Cardiovascular
Diabetes
Diagnostics
Nutrition
Neuromodulation
Pharmaceuticals
Contact:
Address: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064
Tel: (224) 667-6100
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just…
Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the…
In late 2023, The Wall Street Journal published the article Generic Drugs Should Be Cheap, but Insurers Are Charging Thousands of Dollars for Them. This article examined interactions between patient health insurance prescription…
US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is…
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Cardiff Advisory’s David H. Crean outlines the positive atmosphere and sentiment observed at JPM 2024, the annual healthcare financing conference held near San Francisco’s Union Square. Dr. Crean picks up…
Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the…
As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.…
Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma…
As the US Inflation Reduction Act (IRA) starts to become a reality, and both big pharma and biotech companies brace themselves for its more widespread impact, BIO names Washington fixture,…
The US Food and Drug Administration has increasingly recognized the importance of diversity and representation in clinical trials over the past few decades. This evolution reflects growing awareness across medicine…
AI is the buzzword du jour across all industries, but what is needed for it to truly make a difference in clinical trials? Writing in December 2023’s DIA Global Forum…
Eli Lilly has turned its numbers around and become the world’s most valuable pharma company, thanks to its type 2 diabetes and off-label use obesity drug tirzeptide, which generated no…
See our Cookie Privacy Policy Here
